Related StoriesGuide to organoid growthNew equipment to measure S-Adenosylmethionine and methylation indexReady-to-make use of tagged cDNA clonesFor more info on please visit or contact AMSBIO right now on +44-1235-828200 / +1-800-987-0985 or email. Founded in 1987, AMS Biotechnology is recognized today as a respected company contributing to the acceleration of discovery through the provision of cutting-edge life research technology services and products for research and development in the medical, nutrition, energy and cosmetics sectors.Vaishnaw, M.D., Ph.D., Senior Vice Chief and President Medical Officer of Alnylam. ALN-TTR02 utilizes our proprietary second-generation LNP technology which has shown significant potency improvements in both pre-clinical and clinical studies. We quite definitely anticipate our expected reporting of TTR knockdown data from the Phase I research in the 3rd quarter of this season. Related StoriesResearchers identify tumor suppressor genes that get subset of melanomasPerisylvian polymicrogyria gene foundUnderstanding how schizophrenia impacts workings of the mind RNAi therapeutics represent a novel and interesting approach for the treating ATTR, as this new drug modality gets the potential to create a meaningful effect in the treating this devastating disease.